Evidence map›Paper›PMID 23076533›Full record

ArticleMolecular biology reports2013

Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment.

Nur Selvi, Burçin Tezcanlı Kaymaz, Handan Haydaroğlu Sahin, Mustafa Pehlivan, Cağdaş Aktan, Ayşegül Dalmızrak, Ezgi Inalpolat, Buket Kosova, Mehmet Yılmaz, Vahap Okan and 1 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Nur SelviDepartment of Medical Biology, School of Medicine, Ege University, Izmir, Turkey. nur.selvi@ege.edu.tr
Burçin Tezcanlı Kaymaz
Handan Haydaroğlu Sahin
Mustafa Pehlivan
Cağdaş Aktan
Ayşegül Dalmızrak
Ezgi Inalpolat
Buket Kosova
Mehmet Yılmaz
Vahap Okan
Güray Saydam
Ege University · TRGaziantep University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this work was to report two cases of hypereosinophilic syndrome (HES). FIP1L1-PDGFRA fusion was assessed with two protocols at RNA level. The fusion transcript was found positive at the RNA level with both PCR methods in two cases. In this study, the efficiency of imatinib treatment and a dramatic response in two HES cases with multisystemic involvement showing the characteristics of a chronic myeloproliferative disease were presented. Both cases showed complete responses confirming that imatinib mesylate treatment could be successful even in patients with advanced HES having myeloproliferative disease.

Indexed as

BenzamidesHumansHypereosinophilic SyndromeImatinib MesylateMaleMiddle AgedMolecular Diagnostic TechniquesmRNA Cleavage and Polyadenylation FactorsOncogene Proteins, FusionPiperazinesPolymorphism, Restriction Fragment LengthPyrimidinesReal-Time Polymerase Chain ReactionReceptor, Platelet-Derived Growth Factor alphaTreatment OutcomeBenzamidesFIP1L1-PDGFRA fusion protein, humanImatinib MesylatemRNA Cleavage and Polyadenylation FactorsOncogene Proteins, FusionPiperazinesPyrimidinesReceptor, Platelet-Derived Growth Factor alpha

Identifiers

PMID23076533
OpenAlexW2062823004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.